2016

/Tag:2016

Oramed to Present at the Aegis Capital Growth Conference

JERUSALEM, September 19, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Aegis Growth Conference, taking place September 20-22, 2016 in Las Vegas. [...]

2018-05-30T17:04:04+00:00 Categories: Press Releases|Tags: |

Oramed to Present at the Rodman & Renshaw Global Investment Conference

JERUSALEM, September 7, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Rodman & Renshaw 18th Annual Global Investment Conference, taking place [...]

2018-05-30T17:04:05+00:00 Categories: Press Releases|Tags: |

Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo

JERUSALEM, July 28, 2016 /PRNewswire/ -- Statistically Significant Results Across Key Glycemic Endpoints  Conference Call Today at 11:00 AM ET  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a developer of oral drug delivery systems, today reported additional data from the recently concluded Phase IIb trial of [...]

2018-05-30T17:04:05+00:00 Categories: Press Releases|Tags: |

Oramed Appoints Dr. Roy Eldor as Chief Medical Director

JERUSALEM, July 26, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Roy Eldor MD PhD to the newly created position of Chief Medical Director. "We are very pleased to welcome Dr. [...]

2018-05-30T17:04:05+00:00 Categories: Press Releases|Tags: |

Oramed Announces $6.5 Million Milestone Payment from HTIT

Payment comes in wake of positive topline phase IIB results JERUSALEM, June 21, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced that Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT) is transferring a $6.5 million [...]

2018-05-30T17:04:13+00:00 Categories: Press Releases|Tags: |

Oramed to Present at the American Diabetes Association 76th Scientific Sessions

JERUSALEM, June 9, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (https://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing a study performed in animals with its orally ingestible insulin capsule, ORMD-0801, will be [...]

2018-05-30T17:04:14+00:00 Categories: Press Releases|Tags: |